This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations. Treatment is assigned according to tumor genetic findings.
Age ≥18 years.
Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable.
Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.
At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-1.
Stage III NSCLC considered unresectable by surgical assessment.
Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years.
Another malignancy within the previous 5 years.
Major surgery within 28 days before the first study dose.
Parallel
Surgical Resection
Procedure/SurgeryCurative-intent resection following targeted therapy in participants considered suitable for surgery.
6
Treatment groupsSee each treatment group below.
Major Pathological Response Rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
